In 32 of 153 (21%) patients with HMB, who were not known to have a bleeding disorder at their first consultation, coagulation testing revealed a new bleeding disorder, including mild VWD type 1 (n = 21), platelet aggregation defect (n = 8), immune-mediated thrombocytopenia (n = 1), factor VII deficiency (n = 1; FVII 35 IU/mL) and a combination of mild hemophilia A (FVIII:C 0.28 IU/mL) and platelet aggregation defect (n = 1; Figure 2B). This evidence concerns the gene F8 and hemorrhagic disease.